ATLANTA—Lupus nephritis patients who receive rituximab earlier in the course of their disease rather than later have better outcomes, new findings suggest. “We have been trying to use rituximab in a ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adding a cycle ...

Rituximab, a monoclonal antibody that targets the CD20 antigen on B-lymphocytes, may offer therapeutic value in lupus nephritis unresponsive to standard regimens. In patients with relapsed or ...

SAN DIEGO--(BUSINESS WIRE)--Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, ...

Paris, France - Although the B-cell depleter rituximab (Rituxan, MabThera; Genentech/IDEC) is not yet marketed for use in the treatment of autoimmune diseases, it is already being used off label in ...

The Food & Drug Administration (FDA) has granted Fast Track designation to the investigational therapy, AlloNK® (also known as AB-101), to be used in combination with rituximab or obinutuzumab, as a ...

SAN DIEGO--(BUSINESS WIRE)--Artiva Biotherapeutics, Inc., a clinical-stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, ...